{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:20:01Z","timestamp":1789014001176,"version":"build-2803163510"},"reference-count":26,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has facilitated progress in treatment of refractory\/relapsed diffuse large B-cell lymphoma (DLBCL). A well-known adverse event after CAR-T therapy is cytokine release syndrome(CRS). However, the etiology and pathophysiology of CRS-related coagulopathy remain unknown. Therefore, we conducted a prospective cohort study to comprehensively analyze coagulation\/ fibrinolysis parameters present in peripheral blood of adult DLBCL patients treated with tisagenlecleucel in a single institution. Samples were collected from 25 patients at 3 time points: before lymphocyte-depletion chemotherapy and on days 3 and 13 after CAR-T infusion. After infusion, all patients except 1 experienced CRS, and 13 required the administration of tocilizumab. A significant elevation in the plasma level of total plasminogen activator inhibitor 1 (PAI-1), which promotes the initial step of coagulopathy (mean, 22.5 ng\/mL before lymphocyte-depletion and 41.0 on day 3, P = .02), was observed at the onset of CRS. Moreover, this suppressed fibrinolysis-induced relatively hypercoagulable state was gradually resolved after CRS remission with normalization of total PAI-1 to preinfusion levels without any organ damage (mean values of soluble fibrin: 3.16 \u00b5g\/mL at baseline, 8.04 on day 3, and 9.16 on day 13, P &amp;lt; .01; and mean PAI-1: 25.1 ng\/mL on day 13). In conclusion, a hypofibrinolytic and relatively hypercoagulable state concomitant with significant total PAI-1 elevation was observed at the onset of CRS even in DLBCL patients with mild CRS. Our results will facilitate understanding of CRS-related coagulopathy, and they emphasize the importance of monitoring sequential coagulation\/fibrinolysis parameters during CAR-T therapy.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007454","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T16:55:15Z","timestamp":1652806515000},"page":"4216-4223","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4803-9994","authenticated-orcid":false,"given":"Makiko","family":"Yamasaki-Morita","sequence":"first","affiliation":[{"name":"1Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan;"},{"name":"2Department of Clinical Laboratory, Kyoto University Hospital, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-5093","authenticated-orcid":false,"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[{"name":"2Department of Clinical Laboratory, Kyoto University Hospital, Kyoto, Japan;"},{"name":"3Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1061-085X","authenticated-orcid":false,"given":"Takashi","family":"Ishihara","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-7645","authenticated-orcid":false,"given":"Tomoko","family":"Onishi","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanako","family":"Shimo","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, and"},{"name":"5Center for Diversity and Inclusion, Nara Medical University, Kashihara, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0424-4964","authenticated-orcid":false,"given":"Kayoko","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"2Department of Clinical Laboratory, Kyoto University Hospital, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"2Department of Clinical Laboratory, Kyoto University Hospital, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9381-0421","authenticated-orcid":false,"given":"Tomoyasu","family":"Jo","sequence":"additional","affiliation":[{"name":"2Department of Clinical Laboratory, Kyoto University Hospital, Kyoto, Japan;"},{"name":"3Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3136-5670","authenticated-orcid":false,"given":"Hidefumi","family":"Hiramatsu","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5915-7801","authenticated-orcid":false,"given":"Takaya","family":"Mitsuyoshi","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisaki","family":"Mizumoto","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-3633","authenticated-orcid":false,"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4171-2162","authenticated-orcid":false,"given":"Momoko","family":"Nishikori","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2415-2194","authenticated-orcid":false,"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7678-4284","authenticated-orcid":false,"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8886-6145","authenticated-orcid":false,"given":"Miki","family":"Nagao","sequence":"additional","affiliation":[{"name":"2Department of Clinical Laboratory, Kyoto University Hospital, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8473-0187","authenticated-orcid":false,"given":"Souichi","family":"Adachi","sequence":"additional","affiliation":[{"name":"1Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"issue":"2","key":"2022072016271733600_B1","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","article-title":"The European Medicines Agency Review of Kymriah (tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma","volume":"25","author":"Ali","year":"2020","journal-title":"Oncologist."},{"issue":"5","key":"2022072016271733600_B2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med."},{"key":"2022072016271733600_B3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2019-127508","article-title":"Pivotal safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood."},{"issue":"2","key":"2022072016271733600_B4","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: current management and future directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"HemaSphere."},{"issue":"6","key":"2022072016271733600_B5","first-page":"731","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages","volume":"24","author":"Giavridis","year":"2018","journal-title":"Physiol Behav."},{"issue":"7","key":"2022072016271733600_B6","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s12276-021-00649-0","article-title":"Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms","volume":"53","author":"Kang","year":"2021","journal-title":"Exp Mol Med."},{"issue":"36","key":"2022072016271733600_B7","doi-asserted-by":"crossref","first-page":"22351","DOI":"10.1073\/pnas.2010229117","article-title":"IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome","volume":"117","author":"Kang","year":"2020","journal-title":"Proc Natl Acad Sci USA."},{"issue":"16","key":"2022072016271733600_B8","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med."},{"issue":"6","key":"2022072016271733600_B9","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+\u00a0composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest."},{"issue":"4","key":"2022072016271733600_B10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2991\/chi.k.201108.001","article-title":"CART cell toxicities: new insight into mechanisms and management","volume":"2","author":"Zahid","year":"2020","journal-title":"Clin Hematol Int."},{"issue":"2","key":"2022072016271733600_B11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica."},{"issue":"7","key":"2022072016271733600_B12","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","article-title":"Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy","volume":"98","author":"Jiang","year":"2019","journal-title":"Ann Hematol."},{"issue":"2","key":"2022072016271733600_B13","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/bloodadvances.2020002757","article-title":"Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy","volume":"5","author":"Buechner","year":"2021","journal-title":"Blood Adv."},{"issue":"16","key":"2022072016271733600_B14","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med."},{"issue":"5","key":"2022072016271733600_B15","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","article-title":"Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies","volume":"26","author":"Wang","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"8","key":"2022072016271733600_B16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jiac.2015.04.011","article-title":"Phagocytosis by human monocytes is required for the secretion of presepsin","volume":"21","author":"Arai","year":"2015","journal-title":"J Infect Chemother."},{"key":"2022072016271733600_B17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3389\/fimmu.2018.00754","article-title":"Role of C-reactive protein at sites of inflammation and infection","volume":"9","author":"Sproston","year":"2018","journal-title":"Front Immunol."},{"issue":"2","key":"2022072016271733600_B18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1055\/s-0037-1612976","article-title":"The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure","volume":"87","author":"Green","year":"2002","journal-title":"Thromb Haemost."},{"issue":"224","key":"2022072016271733600_B19","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med."},{"issue":"4","key":"2022072016271733600_B20","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1160\/TH04-12-0842","article-title":"Structure and function of the plasminogen\/plasmin system","volume":"93","author":"Castellino","year":"2005","journal-title":"Thromb Haemost."},{"issue":"5","key":"2022072016271733600_B21","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1532\/IJH97.05190","article-title":"Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation","volume":"84","author":"Madoiwa","year":"2006","journal-title":"Int J Hematol."},{"issue":"1","key":"2022072016271733600_B22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/blood-2005-07-2681","article-title":"Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis","volume":"107","author":"Smith","year":"2006","journal-title":"Blood."},{"issue":"9","key":"2022072016271733600_B23","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1111\/jth.15016","article-title":"Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis","volume":"18","author":"Nougier","year":"2020","journal-title":"J Thromb Haemost."},{"issue":"1","key":"2022072016271733600_B24","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41598-020-80010-z","article-title":"Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients","volume":"11","author":"Zuo","year":"2021","journal-title":"Sci Rep."},{"issue":"3","key":"2022072016271733600_B25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.thromres.2011.10.013","article-title":"Sepsis, thrombosis and organ dysfunction","volume":"129","author":"Semeraro","year":"2012","journal-title":"Thromb Res."},{"issue":"21","key":"2022072016271733600_B26","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4216\/1909787\/advancesadv2022007454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4216\/1909787\/advancesadv2022007454.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T12:27:48Z","timestamp":1658320068000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/14\/4216\/485286\/Relative-hypercoagulation-induced-by-suppressed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":26,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,7,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007454","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]}}}